Evaluation of type 1 growth factor receptor family expression in benign and malignant thyroid lesions.

[1]  K. Burman,et al.  Thyroid cancer molecular signaling pathways and use of targeted therapy. , 2007, Endocrinology and metabolism clinics of North America.

[2]  H. Gharib,et al.  Thyroid nodules: clinical importance, assessment, and treatment. , 2007, Endocrinology and metabolism clinics of North America.

[3]  I. Hay.  Selective use of radioactive iodine in the postoperative management of patients with papillary and follicular thyroid carcinoma , 2006, Journal of surgical oncology.

[4]  J. Haley,et al.  Inactivation of Akt by the epidermal growth factor receptor inhibitor erlotinib is mediated by HER-3 in pancreatic and colorectal tumor cell lines and contributes to erlotinib sensitivity , 2006, Molecular Cancer Therapeutics.

[5]  Seungwon Kim,et al.  Dual Epidermal Growth Factor Receptor and Vascular Endothelial Growth Factor Receptor Inhibition with NVP-AEE788 for the Treatment of Aggressive Follicular Thyroid Cancer , 2006, Clinical Cancer Research.

[6]  G. Riggins,et al.  Diagnosis of Suspicious Thyroid Nodules Using Four Protein Biomarkers , 2006, Clinical Cancer Research.

[7]  Louise Davies,et al.  Increasing incidence of thyroid cancer in the United States, 1973-2002. , 2006, JAMA.

[8]  S. Wiseman,et al.  Hemithyroidectomy: the preferred initial surgical approach for management of Hurthle cell neoplasm. , 2006, American journal of surgery.

[9]  S. Wiseman,et al.  Hemithyroidectomy: The Optimal Initial Surgical Approach for Individuals Undergoing Surgery for a Cytological Diagnosis of Follicular Neoplasm , 2006, Annals of surgical oncology.

[10]  L. Schwartz,et al.  Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  K. Nishii,et al.  Expression of erbB receptors mRNA in thyroid tissues. , 2004, Biochimica et biophysica acta.

[12]  R. Perez-soler.  HER1/EGFR targeting: refining the strategy. , 2004, The oncologist.

[13]  E. Kubista,et al.  Co-Expression of ErbB-Family Members in Human Breast Cancer: Her-2/neu is the Preferred Dimerization Candidate in Nodal-positive Tumors , 2003, Breast Cancer Research and Treatment.

[14]  O. Hamid.  Emerging treatments in oncology: focus on tyrosine kinase (erbB) receptor inhibitors. , 2004, Journal of the American Pharmacists Association : JAPhA.

[15]  S. Wiseman,et al.  HER-2/ neu Protein Expression and Gene Alteration in Stage I-IIIA Non–Small-Cell Lung Cancer: A Study of 140 Cases Using a Combination of High Throughput Tissue Microarray, Immunohistochemistry, and Fluorescent In Situ Hybridization , 2003, Diagnostic molecular pathology : the American journal of surgical pathology, part B.

[16]  A. Citri,et al.  The deaf and the dumb: the biology of ErbB-2 and ErbB-3. , 2003, Experimental cell research.

[17]  Z. Baloch,et al.  Intraoperative assessment of thyroid and parathyroid lesions. , 2002, Seminars in diagnostic pathology.

[18]  C Blake Gilks,et al.  Assessment of interlaboratory variation in the immunohistochemical determination of estrogen receptor status using a breast cancer tissue microarray. , 2002, American journal of clinical pathology.

[19]  Lyndsay N Harris,et al.  Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  C. Balch,et al.  AJCC Cancer Staging Manual. 6th ed , 2002 .

[21]  C. Compton,et al.  AJCC Cancer Staging Manual , 2002, Springer New York.

[22]  C. Cheung,et al.  Immunohistochemical Diagnosis of Papillary Thyroid Carcinoma , 2001, Modern Pathology.

[23]  M. Dottorini,et al.  Usefulness of fine‐needle aspiration in the diagnosis of thyroid carcinoma , 2000, Cancer.

[24]  B. Cady.  Presidential address: beyond risk groups--a new look at differentiated thyroid cancer. , 1998, Surgery.

[25]  L. Akslen,et al.  Expression of c-erbB-3 and c-erbB-4 proteins in papillary thyroid carcinomas. , 1996, Cancer research.

[26]  L. Akslen,et al.  Oncoproteins and tumor progression in papillary thyroid carcinoma. Presence of epidermal growth factor receptor, c‐erbB‐2 protein, estrogen receptor related protein, p21‐ras protein, and proliferation indicators in relation to tumor recurrences and patient survival , 1995 .

[27]  Q. Duh,et al.  Epidermal growth factor (EGF)- and transforming growth factor alpha-stimulated invasion and growth of follicular thyroid cancer cells can be blocked by antagonism to the EGF receptor and tyrosine kinase in vitro. , 1995, European journal of endocrinology.

[28]  H. Gharib,et al.  Fine-needle aspiration biopsy of thyroid nodules: advantages, limitations, and effect. , 1994, Mayo Clinic proceedings.

[29]  E. Bergstralh,et al.  Predicting outcome in papillary thyroid carcinoma: development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through 1989. , 1993, Surgery.

[30]  N. Sneige,et al.  Diagnostic pitfalls in thyroid fine‐needle aspiration: A review of 394 cases , 1993, Diagnostic cytopathology.

[31]  C. Begg,et al.  Prognostic factors in differentiated carcinoma of the thyroid gland. , 1992, American journal of surgery.

[32]  B. Song,et al.  Immunohistochemical Demonstration of Epidermal Growth Factor Receptor and Ceruloplasmin in Thyroid Diseases , 1991, Acta pathologica japonica.

[33]  J. Lillehaug,et al.  Absence of abnormalities of the c-erbB-1 and c-erbB-2 proto-oncogenes in human thyroid neoplasia. , 1990, European journal of cancer.

[34]  B. Cady,et al.  An expanded view of risk-group definition in differentiated thyroid carcinoma. , 1988, Surgery.

[35]  H. Gharib,et al.  Fine needle aspiration cytology of the thyroid, 1980 to 1986. , 1987, Acta cytologica.

[36]  S. Noguchi,et al.  Papillary carcinoma of the thyroid I. Developing pattern of metastasis , 1970, Cancer.

[37]  J. Shah,et al.  Papillary carcinoma of the thyroid , 1963 .

[38]  V. Tyler.  The effect of germination on the alkaloid content of Nigella damascena seed. , 1955, Journal of the American Pharmaceutical Association. American Pharmaceutical Association.